Aiping Lyu - Selected Publications#

1. van Wietmarschen H, Yuan K, Lu C, Gao P, Wang J, Xiao C, Yan X, Wang M, Schroen J, Lu A, Xu G, van der Greef J. Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. Journal of Clinical Rheumatology, 2009, 15: 330-7.-

This research has pioneered the application of both genomics and metabolomics in revealing novel biomarkers for different rheumatoid arthritis subtypes that are diagnosed according to Chinese medicine theory. This innovative yet pragmatic approach is therefore recommended in the guidelines for randomized controlled trials for the investigation of the clinical practice of Chinese herbal medicine, published in the Journal of Ethnopharmacology ( The number of citations of this study is 112 in Google Scholar.

2. Jiang M, Chen T, Feng H, Zhang Y, Li L, Zhao A, Niu X, Liang F, Wang M, Zhan J, Lu C, He X, Xiao L, Jia W, Lu A. Serum metabolic signatures of four types of human arthritis. Journal of Proteome Research, 2013, 12: 3769-79. -

To our knowledge, this is the first study to identify the uniqueness of the serum metabolic signature in four major types of arthritis, namely rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and gout. Our study not only highlights the applicability of metabonomic phenotyping as a novel tool for diagnosis and patient stratification, but also demonstrates the significance of biomarker discovery in rheumatology. Our work has been highlighted in four review articles published in Nature Reviews Rheumatology (,,, and a year-in-review published in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI) ( The number of citations of this study is 66 in Google Scholar.

3. Jiang M, Zha Q, Zhang C, Lu C, Yan X, Zhu W, Liu W, Tu S, Hou L, Wang C, Zhang W, Liang Q, Fan B, Yu J, Zhang W, Liu X, Yang J, He X, Li L, Niu X, Liu Y, Guo H, He B, Zhang G, Bian Z, Lu A. Predicting and verifying outcome of Tripterygium wilfordii Hook F. based therapy in rheumatoid arthritis: from open to double-blinded randomized trial. Scientific Reports, 2015, 5: 9700.-

This clinical study has confirmed the high efficacy of Tripterygium wilfordii Hook F. based therapy for the treatment of rheumatoid arthritis. Our data also provide a reference to the Chinese Association of Integrative Medicine to include the Tripterygium wilfordii Hook F. based therapy in the Evidence-based Clinical Practice Guidelines for the treatment of rheumatoid arthritis ( The number of citations of this study is 29 in Google Scholar.

4. Liang C, Li J, Lu C, Xie D, Liu J, Zhong C, Wu X, Dai R, Zhang H, Guan D, Guo B, He B, Li F, He X, Zhang W, Zhang B T, Zhang G, Lu A. HIF1alpha inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis. Nature Communications, 2019, 10: 4579. -

Our study has uncovered a novel molecular mechanism addressing the limited efficacy of Leflunomide on bone erosion in a subgroup of rheumatoid arthritis patients distinguished by aberrantly high serum C-reactive protein (CRP) levels. The research findings have been highlighted by Nature Reviews Rheumatology ( Our study also delineates the mechanism of action underlying the effectiveness of the combination of Ligustrazine and Leflunomide for the treatment of rheumatoid arthritis with high serum CRP. This novel precision medicine-based therapeutic strategy is adopted by the First Affiliated Hospital of Anhui University of Chinese Medicine in Hefei in China, and the efficacy of the treatment has been confirmed in 2000 rheumatoid arthritis patients. The number of citations of this study is 10 in Google Scholar.

5. Liang C, Peng S, Li J, Lu J, Guan D, Jiang F, Lu C, Li F, He X, Zhu H, Au D W T, Yang D, Zhang B T, Lu A, Zhang G. Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis. Nature Communications, 2018, 9: 3428.-

This is the first study to showcase a precision medicine-based bone anabolic strategy for age-related osteoporosis. The discovery of this novel therapeutic strategy has attracted investment support from the Hong Kong HP Precision Medicine Co. Ltd. to develop novel bone anabolic agent to improve spinal fusion. The number of citations of this study 19 in Google Scholar.

6. Liang C, Guo B, Wu H, Shao N, Li D, Liu J, Dang L, Wang C, Li H, Li S, Lau W K, Cao Y, Yang Z, Lu C, He X, Au D W, Pan X, Zhang B T, Lu C, Zhang H, Yue K, Qian A, Shang P, Xu J, Xiao L, Bian Z, Tan W, Liang Z, He F, Zhang L, Lu A, Zhang G. Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. Nature Medicine, 2015, 21: 288-94. -

This study has developed the first nucleic acid aptamer-based osteoblast targeting moiety, CH6 aptamer–functionalized lipid nanoparticles (LNPs), which greatly advances the targeted delivery selectivity of osteogenic siRNAs from the tissue level to cellular level. The research findings have been highlighted in Nature Reviews Rheumatology (, Nature Reviews Endocrinology ( and Nature Reviews Drug Discovery ( More importantly, the technology of LNPs is employed in the space scientific projects held in the China’s first cargo spacecraft Tianzhou-1 ( The number of citations of this study is 197 in Google Scholar.

7. Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang Z K, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang B T, Lu A, Zhang G. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 2017, 8: 1390.-

This work showcased the application of aptamer-drug conjugate (ApDC) for the precision medicine-based personalized Paclitaxel in specific cancer types. The intellectual property right of this novel technology has been transferred to a pharmaceutical company in Hong Kong, INCREASEPHARM (HK) LIMITED, for the development of ApDC as novel anti-cancer therapeutic agents. The number of citations of this study is 99 in Google Scholar.

8. Liang C, Li F, Wang L, Zhang Z K, Wang C, He B, Li J, Chen Z, Shaikh A B, Liu J, Wu X, Peng S, Dang L, Guo B, He X, Au D W T, Lu C, Zhu H, Zhang B T, Lu A, Zhang G. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials, 2017, 147: 68-85.-

This study has developed the first nucleic acid aptamer-based osteosarcoma-targeting moiety. The novelty also lies in the encapsulation of CRISPR/Cas9 plasmids in the osteosarcoma cell-specific aptamer functionalized PEG-PEI-cholesterol lipopolymer. This technology not only provides a vast flexibility in choosing the target gene for editing in tumors, but also demonstrates the translation of CRISPR-Cas9 into clinical practice for cancer treatments. The number of citations of this study is 96 in Google Scholar.

9. Liu J, Dang L, Li D, Liang C, He X, Wu H, Qian A, Yang Z, Au D W, Chiang M W, Zhang B T, Han Q, Yue K K, Zhang H, Lv C, Pan X, Xu J, Bian Z, Shang P, Tan W, Liang Z, Guo B, Lu A, Zhang G. A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts. Biomaterials, 2015, 52: 148-60.-

This study has addressed the problem of the dysregulated microRNAs in osteoclasts that can lead to many skeletal diseases. The world’s first ever oligopeptide-based osteoclast targeting moiety has been designed that can deliver microRNA modulators specifically to the bone resorption surfaces. This study facilitates the clinical translation of microRNA modulators in treating osteoclast-dysfunction-related skeletal diseases. The number of citations of this study is 64 in Google Scholar.

10. Li D, Liu J, Guo B, Liang C, Dang L, Lu C, He X, Cheung H Y, Xu L, Lu C, He B, Liu B, Shaikh A B, Li F, Wang L, Yang Z, Au D W, Peng S, Zhang Z, Zhang B T, Pan X, Qian A, Shang P, Xiao L, Jiang B, Wong C K, Xu J, Bian Z, Liang Z, Guo D A, Zhu H, Tan W, Lu A, Zhang G. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. Nature Communications, 2016, 7: 10872.-

To our knowledge, this is the first few studies to reveal the crosstalk between osteoblast and osteoclast mediated by the osteoclast-derived exosomes. Our study also demonstrates that the inhibition of miR-214-3p in osteoclasts can be used to treat skeletal disorders with decreased bone formation. The number of citations of this study is 304 in Google Scholar.

Imprint Privacy policy « This page (revision-4) was last changed on Monday, 23. May 2022, 13:31 by System
  • operated by